Published in Br J Cancer on July 10, 2012
Cell mates: paracrine and stromal targets for prostate cancer therapy. Nat Rev Urol (2013) 0.87
Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells. J Cell Mol Med (2014) 0.83
Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanism. Neoplasia (2014) 0.82
Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy. Cancer Sci (2016) 0.81
Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib. J Cell Mol Med (2014) 0.81
Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma. Oncotarget (2015) 0.77
CCL2 promotes integrin-mediated adhesion of prostate cancer cells in vitro. World J Urol (2014) 0.76
Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer. Int J Mol Sci (2017) 0.75
Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro. Oncotarget (2016) 0.75
Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol (2009) 13.89
Mechanisms of motility in metastasizing cells. Mol Cancer Res (2010) 2.42
A molecular switch that controls cell spreading and retraction. J Cell Biol (2007) 1.93
Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res (2008) 1.83
Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res (2010) 1.74
Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res (2011) 1.67
Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets (2009) 1.66
Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate (2006) 1.57
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res (2011) 1.56
β₁Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J Clin Invest (2012) 1.56
Integrin alpha2-mediated ERK and calpain activation play a critical role in cell adhesion and motility via focal adhesion kinase signaling: identification of a novel signaling pathway. J Biol Chem (2006) 1.44
Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer. PLoS One (2010) 1.40
Cell adaptive response to extracellular matrix density is controlled by ICAP-1-dependent beta1-integrin affinity. J Cell Biol (2008) 1.39
β1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin Cancer Res (2011) 1.23
Integrin subunits alpha5 and alpha6 regulate cell cycle by modulating the chk1 and Rb/E2F pathways to affect breast cancer metastasis. Mol Cancer (2011) 1.17
Pilot study of rapamycin in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer (2008) 1.12
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res (2010) 1.09
Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. Cancer Res (2005) 1.09
Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One (2010) 1.08
Reorganization of the integrin alpha2 subunit controls cell adhesion and cancer cell invasion in prostate cancer. Int J Oncol (2009) 1.05
Snail negatively regulates cell adhesion to extracellular matrix and integrin expression via the MAPK pathway in prostate cancer cells. Cell Adh Migr (2011) 1.02
Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. J Cell Biochem (2010) 1.01
Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival. Anticancer Res (2010) 0.98
Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer. J Urol (2011) 0.96
DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance. PLoS One (2011) 0.96
Inhibition of migration and invasion of LNCaP human prostate carcinoma cells by cordycepin through inactivation of Akt. Int J Oncol (2012) 0.95
Receptor-specific mechanisms regulate phosphorylation of AKT at Ser473: role of RICTOR in β1 integrin-mediated cell survival. PLoS One (2012) 0.95
The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line. Cancer Lett (2011) 0.95
Beta1 integrins mediate cell proliferation in three-dimensional cultures by regulating expression of the sonic hedgehog effector protein, GLI1. J Cell Physiol (2010) 0.93
Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells. Endocr Relat Cancer (2010) 0.93
Tensins: a new switch in cell migration. Dev Cell (2007) 0.91
Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int (2009) 0.90
Priming and potentiation of DNA damage response by fibronectin in human colon cancer cells and tumor-derived myofibroblasts. Int J Oncol (2011) 0.89
Tyrosine phosphorylation as a conformational switch: a case study of integrin β3 cytoplasmic tail. J Biol Chem (2011) 0.89
Collagen IV significantly enhances migration and transplantation of embryonic stem cells: involvement of α2β1 integrin-mediated actin remodeling. Cell Transplant (2010) 0.86
DNAzymes to mouse beta1 integrin mRNA in vivo: targeting the tumor vasculature and retarding cancer growth. Cancer Gene Ther (2009) 0.83
Suppression of α5 gene expression is closely related to the tumorigenic properties of uveal melanoma cell lines. Pigment Cell Melanoma Res (2011) 0.82
Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC). PLoS One (2011) 0.81
Targeting beta1 integrin restores sensitivity to docetaxel of esophageal squamous cell carcinoma. Oncol Rep (2008) 0.79
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 3.43
The efficacy of dihydrotestosterone transdermal gel before primary hypospadias surgery: a prospective, controlled, randomized study. J Urol (2007) 2.85
Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med (1993) 2.85
Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer (1999) 2.34
Detection of prostate cancer with a microbubble ultrasound contrast agent. Lancet (2001) 2.23
Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med (1997) 2.14
Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol (2000) 2.11
Evaluation and management of renal injuries: consensus statement of the renal trauma subcommittee. BJU Int (2004) 2.09
Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res (1998) 2.07
Urinary incontinence in the elderly and age-dependent apoptosis of rhabdosphincter cells. Lancet (1999) 1.92
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol (1993) 1.73
Androgen receptors in prostate cancer. Endocr Relat Cancer (2002) 1.71
New onset hypertension after extracorporeal shock wave lithotripsy: age related incidence and prediction by intrarenal resistive index. J Urol (1997) 1.70
A genetic linkage map of the baboon (Papio hamadryas) genome based on human microsatellite polymorphisms. Genomics (2000) 1.66
Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res (1995) 1.63
Neobladder emptying failure in males: incidence, etiology and therapeutic options. J Urol (2006) 1.61
Urethra-sparing cystectomy and orthotopic urinary diversion in women with malignant pelvic tumors. Cancer (2001) 1.58
Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine (1998) 1.56
The expanding Lyme Borrelia complex--clinical significance of genomic species? Clin Microbiol Infect (2011) 1.55
Googling caesarean section: a survey on the quality of the information available on the Internet. BJOG (2014) 1.54
Testicular torsion: late results with special regard to fertility and endocrine function. J Urol (1980) 1.52
Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors. J Pathol (1997) 1.52
Sildenafil modulates hemodynamics and pulmonary gas exchange. Am J Respir Crit Care Med (2001) 1.50
Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib. Leukemia (2005) 1.48
Laparoscopic surgery for pheochromocytoma: adrenalectomy, partial resection, excision of paragangliomas. J Urol (1998) 1.47
Pilot scale production of a human monoclonal antibody against human immunodeficiency virus HIV-1. J Biochem Biophys Methods (1990) 1.46
Genes differentially expressed in prostate cancer. BJU Int (2004) 1.45
Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro. Prostate Cancer Prostatic Dis (2012) 1.43
A comparison of chilled and room temperature cabbage leaves in treating breast engorgement. J Hum Lact (1995) 1.43
Regulation of prostatic growth and function by peptide growth factors. Prostate (1996) 1.42
Lich-Gregoir reimplantation causes less discomfort than Politano-Leadbetter technique: Results of a prospective, randomized, pain scale-oriented study in a pediatric population. Eur Urol (2005) 1.39
The relation between the effects of veratridine on action potential and contraction in mammalian ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol (1975) 1.34
Extracorporeal shock wave lithotripsy versus ureteroscopy for distal ureteral calculi: a prospective randomized study. J Urol (1999) 1.33
Involvement of cyclic AMP in the direct inotropic action of amrinone. Biochemical and functional evidence. Naunyn Schmiedebergs Arch Pharmacol (1981) 1.32
[Influence of the frequency of contraction on the action potential of the guinea pig papillary muscle]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1968) 1.31
[The effect of sodium ions in the relationship between frequency and force of the contraction of isolated guinea pig myocardium]. Naunyn Schmiedebergs Arch Pharmakol Exp Pathol (1966) 1.27
Higher expression of glucocorticoid receptor in peripheral mononuclear cells in inflammatory bowel disease. Am J Gastroenterol (2000) 1.26
Androgen receptor--an update of mechanisms of action in prostate cancer. Urol Res (2000) 1.25
Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology (2001) 1.24
Impairment of cell-mediated immune responses by Pseudomonas aeruginosa. Clin Exp Immunol (1971) 1.24
The female urethral sphincter: a morphological and topographical study. J Urol (1998) 1.24
Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. J Urol (2000) 1.24
Radical prostatectomy: the value of preoperative, individually labeled apical biopsies. J Urol (2000) 1.23
Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther (2000) 1.21
Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol (1999) 1.20
Treatment of giant ancient pelvic schwannoma. Tech Urol (2001) 1.20
Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate (1998) 1.19
Posttraumatic posterior urethral stricture repair: anatomy, surgical approach and long-term results. J Urol (1997) 1.19
Bacillus Calmette-Guérin mycobacteria stimulate human blood dendritic cells. Int J Cancer (1997) 1.19
Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology (2001) 1.18
Laparoscopic nephron sparing surgery for small renal cell carcinoma. J Urol (1998) 1.17
Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut (2002) 1.17
Androgen receptor status of lymph node metastases from prostate cancer. Prostate (1996) 1.16
Crossing vessels at the ureteropelvic junction: detection with contrast-enhanced color Doppler imaging. Radiology (1999) 1.16
Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer (1996) 1.13
Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res (2001) 1.13
Transurethral prostatectomy: mortality and morbidity. Prostate (1996) 1.13
Relaxant effects on tracheal and ileal smooth muscles of the guinea pig. Arzneimittelforschung (1985) 1.13
delta Antigen in hepatitis B: immunohistology of frozen and paraffin-embedded liver biopsies and relation to HBV infection. Hepatology (1981) 1.12
Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate (2000) 1.12
Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo. J Clin Invest (2001) 1.11
Esophageal pacing: a diagnostic and therapeutic tool. Circulation (1982) 1.10
Cough-cardiopulmonary resuscitation in the cardiac catheterization laboratory: hemodynamics during an episode of prolonged hypotensive ventricular tachycardia. Cathet Cardiovasc Diagn (1989) 1.10
Thalidomide for treatment of severe intestinal bleeding. Gut (2004) 1.09
Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol (1979) 1.08
Isolated right-sided varicocele as a salvage pathway for portal hypertension. Int J Clin Pract (2005) 1.08
Primary lymphatic metastatic spread in testicular cancer occurs ventral to the lumbar vessels. Urology (2002) 1.07
Morphometry in experimental pathology: methods, baseline data and applications. Int Rev Exp Pathol (1976) 1.07
Comparison of protein A, protein G and copolymerized hydroxyapatite for the purification of human monoclonal antibodies. J Chromatogr (1989) 1.07
Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score. J Urol (2007) 1.07
Laparoscopic partial adrenalectomy in patients with aldosterone-producing adenomas: indications, technique, and results. Urology (2003) 1.06
Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma. J Urol (1996) 1.05
Orgotein: a new antiinflammatory metalloprotein drug evaluation of clinical efficacy and safety in inflammatory conditions of the urinary tract. Int Urol Nephrol (1974) 1.04
Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma. Oncogene (2011) 1.03
Cardiac action potential and inotropic effect of noradrenaline and calcium. Naunyn Schmiedebergs Arch Pharmacol (1975) 1.02
Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr Relat Cancer (2005) 1.02
Age dependent apoptosis and loss of rhabdosphincter cells. J Urol (2000) 1.01
DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate (1993) 1.01
Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur Urol (2001) 1.01
Cytomegalovirus- and interferon-related effects on human endothelial cells. Cytomegalovirus infection reduces upregulation of HLA class II antigen expression after treatment with interferon-gamma. Hum Immunol (1992) 1.00
Quality of life after cystectomy and orthotopic neobladder versus ileal conduit urinary diversion. World J Urol (2000) 1.00
Androgen signal transduction and prostatic carcinoma. World J Urol (1994) 1.00
Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors. J Steroid Biochem Mol Biol (1993) 1.00
Excitation-contraction coupling in rested-state contractions of guinea-pig ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol (1984) 1.00
Upgrading of Gleason score 6 prostate cancers on biopsy after prostatectomy in the low and intermediate tPSA range. Prostate Cancer Prostatic Dis (2009) 0.99
Changing diagnostic and therapeutic concepts in high-flow priapism. Int J Impot Res (2005) 0.99
Laparoscopic and retroperitoneoscopic repair of ureteropelvic junction obstruction. Urology (1996) 0.98
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Eur Urol (1995) 0.98
[Evaluation of inotropically active drugs on isolated papillary muscle]. Arzneimittelforschung (1967) 0.97
Anatomic and functional studies of the male and female urethral sphincter. World J Urol (2000) 0.97
Development of a Vero cell-derived influenza whole virus vaccine. Dev Biol Stand (1999) 0.97